B-cell tolerance in transplantation: is repertoire remodeling the answer?

References

• Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med.355(19), 1967–1977 (2006).
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation63(7), 977–983 (1997).
   PubMed Web of Science ®Google Scholar
• Luan FL, Steffick DE, Ojo AO. Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs69(11), 1483–1512 (2009).
   PubMed Web of Science ®Google Scholar
• Scherer MN, Banas B, Mantouvalou K et al. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch. Surg.392(5), 511–523 (2007).
   PubMed Web of Science ®Google Scholar
• Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med.358(4), 362–368 (2008).
   PubMed Web of Science ®Google Scholar
• Fudaba Y, Spitzer TR, Shaffer J et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant.6(9), 2121–2133 (2006).
   PubMed Web of Science ®Google Scholar
• Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl. Int.21(12), 1118–1135 (2008).
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation86(3), 377–383 (2008).
   PubMed Web of Science ®Google Scholar
• Porcheray F, Wong W, Saidman SL et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am. J. Transplant.9(9), 2126–2135 (2009).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin. Transplant.20(1), 48–54 (2006).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Sarwal M. ‘To B or not to B?’ B cells and graft rejection. Transplantation85(12), 1705–1714 (2008).
   PubMed Web of Science ®Google Scholar
• Wood KJ. Is B-cell tolerance essential for transplantation tolerance? Transplantation79(Suppl. 3), S40–S42 (2005).
   Web of Science ®Google Scholar
• Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol. Rev.196, 197–218 (2003).
   PubMed Web of Science ®Google Scholar
• Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol.20(6), 632–638 (2008).
   PubMed Web of Science ®Google Scholar
• Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol.5(10), 807–817 (2005).
   PubMed Web of Science ®Google Scholar
• Monroe JG. Molecular mechanisms regulating B-cell responsiveness and tolerance. Transplantation79(Suppl. 3), S12–S13 (2005).
   PubMed Web of Science ®Google Scholar
• Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl. Int.19(8), 621–628 (2006).
   PubMed Web of Science ®Google Scholar
• Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med.349(2), 125–138 (2003).
   PubMed Web of Science ®Google Scholar
• Colvin RB. Pathology of chronic humoral rejection. Contrib. Nephrol.162, 75–86 (2009).
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant.4(3), 438–443 (2004).
   PubMed Web of Science ®Google Scholar
• Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation87(10), 1505–1513 (2009).
   PubMed Web of Science ®Google Scholar
• Wang R, Wang H, Chen J et al. C4d deposition in allograft renal biopsies is an independent risk factor for graft failure. Nephrology (Carlton)14(5), 527–532 (2009).
   PubMed Web of Science ®Google Scholar
• Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am. J. Transplant.9(4), 812–819 (2009).
   PubMed Web of Science ®Google Scholar
• Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol.5(3), 230–242 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol.9(1), 39–46 (2009).
   PubMed Web of Science ®Google Scholar
• Rasheed AU, Rahn HP, Sallusto F, Lipp M, Muller G. Follicular B helper T-cell activity is confined to CXCR5hiICOShi CD4 T-cells and is independent of CD57 expression. Eur. J. Immunol.36(7), 1892–1903 (2006).
   PubMed Web of Science ®Google Scholar
• McCausland MM, Yusuf I, Tran H, Ono N, Yanagi Y, Crotty S. SAP regulation of follicular helper CD4 T-cell development and humoral immunity is independent of SLAM and Fyn kinase. J. Immunol.178(2), 817–828 (2007).
   PubMed Web of Science ®Google Scholar
• Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood104(7), 1952–1960 (2004).
   PubMed Web of Science ®Google Scholar
• Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation88(4), 568–574 (2009).
   PubMed Web of Science ®Google Scholar
• Mizutani K, Terasaki P, Rosen A et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am. J. Transplant.5(9), 2265–2272 (2005).
   PubMed Web of Science ®Google Scholar
• Sureshkumar KK, Hussain SM, Zimmer BW, Marcus RJ. Emerging role of alemtuzumab in renal and renal-pancreas transplantation. Expert Opin. Biol. Ther.8(10), 1605–1625 (2008).
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas–kidney transplantation comparison with rabbit antithymocyte globulin induction – long-term results. Am. J. Transplant.6(2), 331–339 (2006).
   PubMed Web of Science ®Google Scholar
• Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation78(6), 919–924 (2004).
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant.3(6), 722–730 (2003).
   PubMed Web of Science ®Google Scholar
• Fan X, Ang A, Pollock-Barziv SM et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat. Med.10(11), 1227–1233 (2004).
   PubMed Web of Science ®Google Scholar
• West LJ. B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation81(3), 301–307 (2006).
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Yamashita K, Suzuki T et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am. J. Transplant.9(8), 1732–1741 (2009).
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med.360(25), 2683–2685 (2009).
   PubMed Web of Science ®Google Scholar
• Tarlinton DM, Batista F, Smith KG. The B-cell response to protein antigens in immunity and transplantation. Transplantation85(12), 1698–1704 (2008).
   PubMed Web of Science ®Google Scholar
• Liu C, Noorchashm H, Sutter JA et al. B-lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat. Med.13(11), 1295–1298 (2007).
   PubMed Web of Science ®Google Scholar
• Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J. Immunol.176(11), 6405–6410 (2006).
   PubMed Web of Science ®Google Scholar
• Crowley JE, Scholz JL, Quinn WJ 3rd et al. Homeostatic control of B-lymphocyte subsets. Immunol. Res.42(1–3), 75–83 (2008).
   PubMed Web of Science ®Google Scholar
• Osmond DG, Rolink A, Melchers F. Murine B lymphopoiesis: towards a unified model. Immunol. Today19(2), 65–68 (1998).
   PubMedGoogle Scholar
• Osmond DG, Rico-Vargas S, Valenzona H et al. Apoptosis and macrophage-mediated cell deletion in the regulation of B lymphopoiesis in mouse bone marrow. Immunol. Rev.142, 209–230 (1994).
   PubMed Web of Science ®Google Scholar
• Osmond DG, Melchers F, Paige CJ. Pre-B cells in mouse bone marrow: in vitro maturation of peanut agglutinin binding B-lymphocyte precursors separated from bone marrow by fluorescence-activated cell sorting. J. Immunol.133(1), 86–90 (1984).
   PubMed Web of Science ®Google Scholar
• Osmond DG. Population dynamics of bone marrow B-lymphocytes. Immunol. Rev.93, 103–124 (1986).
   PubMed Web of Science ®Google Scholar
• Melchers F, Rolink A, Grawunder U et al. Positive and negative selection events during B lymphopoiesis. Curr. Opin. Immunol.7(2), 214–227 (1995).
   PubMed Web of Science ®Google Scholar
• Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B-cell stages in normal mouse bone marrow. J. Exp. Med.173(5), 1213–1225 (1991).
   PubMed Web of Science ®Google Scholar
• Hardy RR, Li YS, Allman D, Asano M, Gui M, Hayakawa K. B-cell commitment, development and selection. Immunol. Rev.175, 23–32 (2000).
   PubMed Web of Science ®Google Scholar
• Li Y, Ma L, Shen J, Chong AS. Peripheral deletion of mature alloreactive B cells induced by costimulation blockade. Proc. Natl Acad. Sci. USA104(29), 12093–12098 (2007).
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature435(7042), 590–597 (2005).
   PubMed Web of Science ®Google Scholar
• Goodnow CC. Nossal and Pike 1975: a turning point in the effort to define self-tolerance mechanisms. J. Immunol.179(9), 5617–5618 (2007).
   PubMed Web of Science ®Google Scholar
• Nossal GJ, Pike BL. Evidence for the clonal abortion theory of B-lymphocyte tolerance. J. Exp. Med.141(4), 904–917 (1975).
   PubMed Web of Science ®Google Scholar
• Norvell A, Mandik L, Monroe JG. Engagement of the antigen-receptor on immature murine B-lymphocytes results in death by apoptosis. J. Immunol.154(9), 4404–4413 (1995).
   PubMed Web of Science ®Google Scholar
• Nemazee DA, Burki K. Clonal deletion of B-lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature337(6207), 562–566 (1989).
   PubMed Web of Science ®Google Scholar
• Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B-lymphocytes recognizing membrane-bound antigens. Nature353(6346), 765–769 (1991).
   PubMed Web of Science ®Google Scholar
• Nemazee D, Buerki K. Clonal deletion of autoreactive B-lymphocytes in bone marrow chimeras. Proc. Natl Acad. Sci. USA86(20), 8039–8043 (1989).
   PubMed Web of Science ®Google Scholar
• Russell DM, Dembic Z, Morahan G, Miller JF, Burki K, Nemazee D. Peripheral deletion of self-reactive B cells. Nature354(6351), 308–311 (1991).
   PubMed Web of Science ®Google Scholar
• Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature371(6496), 389–395 (1994).
   PubMed Web of Science ®Google Scholar
• Shokat KM, Goodnow CC. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature375(6529), 334–338 (1995).
   PubMed Web of Science ®Google Scholar
• Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B-cell fate. Immunity3(6), 691–701 (1995).
   PubMed Web of Science ®Google Scholar
• Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: toward a molecular understanding of B-cell homeostasis. Cell Biochem. Biophys53(1), 1–16 (2009).
   PubMed Web of Science ®Google Scholar
• Miosge LA, Goodnow CC. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol. Cell Biol.83(4), 318–335 (2005).
   PubMed Web of Science ®Google Scholar
• Rolink AG, Schaniel C, Andersson J, Melchers F. Selection events operating at various stages in B-cell development. Curr. Opin. Immunol.13(2), 202–207 (2001).
   PubMed Web of Science ®Google Scholar
• Louzoun Y, Friedman T, Luning Prak E, Litwin S, Weigert M. Analysis of B-cell receptor production and rearrangement. Part I. Light chain rearrangement. Semin. Immunol.14(3), 169–190; discussion 221–122 (2002).
   PubMed Web of Science ®Google Scholar
• Liu Y, Li L, Kumar KR et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J. Immunol.179(2), 1340–1352 (2007).
   PubMed Web of Science ®Google Scholar
• Verkoczy LK, Martensson AS, Nemazee D. The scope of receptor editing and its association with autoimmunity. Curr. Opin. Immunol.16(6), 808–814 (2004).
   PubMed Web of Science ®Google Scholar
• Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med.177(4), 999–1008 (1993).
   PubMed Web of Science ®Google Scholar
• Kouskoff V, Lacaud G, Pape K, Retter M, Nemazee D. B-cell receptor expression level determines the fate of developing B-lymphocytes: receptor editing versus selection. Proc. Natl Acad. Sci. USA97(13), 7435–7439 (2000).
   PubMed Web of Science ®Google Scholar
• Stadanlick JE, Kaileh M, Karnell FG et al. Tonic B-cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat. Immunol.9(12), 1379–1387 (2008).
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Crosbie J, Adelstein S et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature334(6184), 676–682 (1988).
   PubMed Web of Science ®Google Scholar
• Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature349(6307), 331–334 (1991).
   PubMed Web of Science ®Google Scholar
• Treml LS, Quinn WJ 3rd, Treml JF, Scholz JL, Cancro MP. Manipulating B-cell homeostasis: a key component in the advancement of targeted strategies. Arch. Immunol. Ther. Exp. (Warsz)56(3), 153–164 (2008).
   PubMed Web of Science ®Google Scholar
• Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B-lymphocyte stimulator that is mutated in a mouse strain with severe B-cell deficiency. Curr. Biol.11(19), 1547–1552 (2001).
   PubMed Web of Science ®Google Scholar
• Smith SH, Cancro MP. Cutting edge: B-cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J. Immunol.170(12), 5820–5823 (2003).
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med.190(11), 1697–1710 (1999).
   PubMed Web of Science ®Google Scholar
• Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B-lymphocytes. J. Exp. Med.192(10), 1453–1466 (2000).
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B-lymphocyte stimulator. Science285(5425), 260–263 (1999).
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J. Exp. Med.189(11), 1747–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Warnatz K, Salzer U, Rizzi M et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl Acad. Sci. USA106(33), 13945–13950 (2009).
   PubMed Web of Science ®Google Scholar
• Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev.204, 43–54 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol.168(12), 5993–5996 (2002).
   PubMed Web of Science ®Google Scholar
• Enzler T, Bonizzi G, Silverman GJ et al. Alternative and classical NF-κ B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity25(3), 403–415 (2006).
   PubMed Web of Science ®Google Scholar
• Hatada EN, Do RK, Orlofsky A et al. NF-κ B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-κ B2 p100 to p52 in quiescent mature B cells. J. Immunol.171(2), 761–768 (2003).
   PubMed Web of Science ®Google Scholar
• Woodland RT, Fox CJ, Schmidt MR et al. Multiple signaling pathways promote B-lymphocyte stimulator dependent B-cell growth and survival. Blood111(2), 750–760 (2008).
   PubMed Web of Science ®Google Scholar
• Day ES, Cachero TG, Qian F et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry44(6), 1919–1931 (2005).
   PubMed Web of Science ®Google Scholar
• Cao M, Chen L, Shan XX, Zhang SQ. Immunological effects of refolded human soluble BAFF synthesized in Escherichia coli on murine B-lymphocytes in vitro and in vivo. Jpn J. Physiol.55(4), 221–227 (2005).
   PubMedGoogle Scholar
• Hymowitz SG, Patel DR, Wallweber HJ et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem.280(8), 7218–7227 (2005).
   PubMed Web of Science ®Google Scholar
• Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov.5(3), 235–246 (2006).
   PubMed Web of Science ®Google Scholar
• Harless SM, Lentz VM, Sah AP et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B-lymphocyte numbers. Curr. Biol.11(24), 1986–1989 (2001).
   PubMed Web of Science ®Google Scholar
• Shulga-Morskaya S, Dobles M, Walsh ME et al. B-cell-activating factor belonging to the TNF family acts through separate receptors to support B-cell survival and T-cell-independent antibody formation. J. Immunol.173(4), 2331–2341 (2004).
   PubMed Web of Science ®Google Scholar
• Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity21(5), 629–642 (2004).
   PubMed Web of Science ®Google Scholar
• Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol.24(6), 343–349 (2003).
   PubMed Web of Science ®Google Scholar
• Yu M, Parsons RF, Rostami Set al.In vivo BLyS/BAFF neutralization induces donor specific transplantation tolerance to murine islet allografts. Am. J. Transplant.9(Suppl. 2), 728 (2009).
   Google Scholar
• Morecki S, Leshem B, Eid A, Slavin S. Alloantigen persistence in induction and maintenance of transplantation tolerance. J. Exp. Med.165(6), 1468–1480 (1987).
   PubMed Web of Science ®Google Scholar
• Hamano K, Rawsthorne MA, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation62(6), 856–860 (1996).
   PubMed Web of Science ®Google Scholar
• Lang J, Nemazee D. B-cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. Eur. J. Immunol.30(2), 689–696 (2000).
   PubMed Web of Science ®Google Scholar
• Sykes M, Shimizu I, Kawahara T. Mixed hematopoietic chimerism for the simultaneous induction of T and B-cell tolerance. Transplantation79(Suppl. 3), S28–S29 (2005).
   Web of Science ®Google Scholar
• Yang YG, deGoma E, Ohdan H et al. Tolerization of anti-Galα1–3Gal natural antibody-forming B cells by induction of mixed chimerism. J. Exp. Med.187(8), 1335–1342 (1998).
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant.7(2), 408–415 (2007).
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol.182(12), 7459–7472 (2009).
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest.118(10), 3420–3430 (2008).
   PubMed Web of Science ®Google Scholar
• Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu. Rev. Immunol.11, 165–190 (1993).
   PubMed Web of Science ®Google Scholar
• Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B-cell development and autoimmune disease. Impaired B-cell maturation in mice lacking BLyS. Immunity15(2), 289–302 (2001).
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity20(6), 785–798 (2004).
   PubMed Web of Science ®Google Scholar
• Brink R. Regulation of B-cell self-tolerance by BAFF. Semin. Immunol.18(5), 276–283 (2006).
   PubMed Web of Science ®Google Scholar
• Quinn WJ 3rd, Noorchashm N, Crowley JE et al. Cutting edge: impaired transitional B-cell production and selection in the nonobese diabetic mouse. J. Immunol.176(12), 7159–7164 (2006).
   PubMed Web of Science ®Google Scholar
• Zekavat G, Rostami SY, Badkerhanian Aet al.In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol.181(11), 8133–8144 (2008).
   PubMed Web of Science ®Google Scholar
• Kahn P, Ramanujam M, Bethunaickan R et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum.58(9), 2824–2834 (2008).
   PubMedGoogle Scholar
• Marino E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST. CD4+CD25+ T-cells control autoimmunity in the absence of B cells. Diabetes58(7), 1568–1577 (2009).
   PubMed Web of Science ®Google Scholar
• Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther.8(11), 1805–1814 (2008).
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a Phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther.10(5), R109 (2008).
   PubMed Web of Science ®Google Scholar
• Dorner T. Crossroads of B-cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl.77, 3–11 (2006).
   PubMedGoogle Scholar
• Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs7(5), 464–472 (2006).
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B-cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis.66(5), 700–703 (2007).
   PubMed Web of Science ®Google Scholar
• Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B-lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B-cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum.54(3), 723–732 (2006).
   PubMed Web of Science ®Google Scholar
• Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum.56(5), 1464–1477 (2007).
   PubMed Web of Science ®Google Scholar
• Sundberg A, Samaniego M, Pirsch J et al. A pilot study of campath-1H and rituximab induction therapy combined with Cellcept to allow for a calcineurin inhibitor-free regimen after renal transplantation. Am. J. Transplant.9(Suppl. 2), 258 (2009).
   PubMedGoogle Scholar
• Bloom DD, Pauly K, Chang Z et al. BAFF dysregulation in renal transplant patients treated with campath-1H. Am. J. Transplant.9(Suppl. 2), 226 (2009).
   Google Scholar
• Bloom D, Chang Z, Pauly K et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am. J. Transplant.9(8), 1835–1845 (2009).
   PubMed Web of Science ®Google Scholar
• Xu H, He X, Liu Q et al. The abnormal high expression of B-cell activating factor belonging to TNF superfamily (BAFF) and its potential role in kidney transplant recipients. Cell Mol. Immunol.5(6), 465–470 (2008).
   PubMed Web of Science ®Google Scholar
• Xu H, He X, Liu Q et al. Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc.41(5), 1552–1556 (2009).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Sarwal MM. Microarrays: monitoring for transplant tolerance and mechanistic insights. Clin. Lab. Med.28(3), 385–410, vi (2008).
   PubMed Web of Science ®Google Scholar
• Cambridge G, Leandro MJ, Teodorescu M et al. B-cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum.54(11), 3612–3622 (2006).
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation86(12), 1754–1761 (2008).
   PubMed Web of Science ®Google Scholar
• Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (campath 1H) induction therapy in cadaveric kidney transplantation – efficacy and safety at five years. Am. J. Transplant.5(6), 1347–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Basu A, Ramkumar M, Tan HP et al. Reversal of acute cellular rejection after renal transplantation with campath-1H. Transplant Proc.37(2), 923–926 (2005).
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Friend PJ, Calne RY et al. Alemtuzumab (campath-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation87(7), 1092–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem.76, 1–22 (2007).
   PubMed Web of Science ®Google Scholar
• Rajewsky K. Clonal selection and learning in the antibody system. Nature381(6585), 751–758 (1996).
   PubMed Web of Science ®Google Scholar
• Tarlinton D, Radbruch A, Hiepe F, Dorner T. Plasma cell differentiation and survival. Curr. Opin. Immunol.20(2), 162–169 (2008).
   PubMed Web of Science ®Google Scholar
• Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B-cell segregation between the outer and centre follicle. Nature460(7259), 1122–1126 (2009).
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Ueki K, Tobe K et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature390(6655), 91–96 (1997).
   PubMed Web of Science ®Google Scholar
• Zubler RH. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Semin. Immunopathol.23(4), 405–419 (2001).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Oliveira EM, Anderson DE et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J. Immunol.167(10), 5669–5677 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson SM, Tomayko MM, Ahuja A, Haberman AM, Shlomchik MJ. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med.204(9), 2103–2114 (2007).
   PubMed Web of Science ®Google Scholar
• Lopes-Carvalho T, Kearney JF. Marginal zone B-cell physiology and disease. Curr. Dir. Autoimmun.8, 91–123 (2005).
   PubMedGoogle Scholar
• Stephens R, Ndungu FM, Langhorne J. Germinal centre and marginal zone B cells expand quickly in a second Plasmodium chabaudi malaria infection producing mature plasma cells. Parasite Immunol.31(1), 20–31 (2009).
   PubMed Web of Science ®Google Scholar
• Miller DJ, Hayes CE. Phenotypic and genetic characterization of a unique B-lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol.21(5), 1123–1130 (1991).
   PubMed Web of Science ®Google Scholar
• Miller DJ, Hanson KD, Carman JA, Hayes CE. A single autosomal gene defect severely limits IgG but not IgM responses in B-lymphocyte-deficient A/WySnJ mice. Eur. J. Immunol.22(2), 373–379 (1992).
   PubMed Web of Science ®Google Scholar
• Rahman ZS, Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J. Immunol.173(10), 6179–6188 (2004).
   PubMed Web of Science ®Google Scholar
• Benson MJ, Dillon SR, Castigli E et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol.180(6), 3655–3659 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med.199(1), 91–98 (2004).
   PubMed Web of Science ®Google Scholar
• Moreaux J, Cremer FW, Reme T et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood106(3), 1021–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Scholz JL, Crowley JE, Tomayko MM et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad. Sci. USA105(40), 15517–15522 (2008).
   PubMed Web of Science ®Google Scholar
• Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA105(12), 4802–4807 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med.102(2), 157–177 (1955).
   PubMed Web of Science ®Google Scholar
• Di Rosa F, Matzinger P. Long-lasting CD8 T-cell memory in the absence of CD4 T-cells or B cells. J. Exp. Med.183(5), 2153–2163 (1996).
   PubMed Web of Science ®Google Scholar
• Brandle D, Joergensen J, Zenke G, Burki K, Hof RP. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B-cell-deficient mice. Transplantation65(11), 1489–1493 (1998).
   PubMed Web of Science ®Google Scholar
• Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B-lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B-cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med.192(4), 475–482 (2000).
   PubMed Web of Science ®Google Scholar
• Wasowska BA, Qian Z, Cangello DL et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation71(6), 727–736 (2001).
   PubMed Web of Science ®Google Scholar
• Noorchashm H, Reed AJ, Rostami SY et al. B-cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J. Immunol.177(11), 7715–7722 (2006).
   PubMed Web of Science ®Google Scholar
• Ng YH, Li Q, Marlowe A, Hoffman R, Chalasani G. Antigen presentation by B cells promotes heart allograft rejection and development of alloreactive memory T-cells. Am. J. Transplant.8(Suppl. 2), 177–336 (2008).
   PubMedGoogle Scholar
• Burns AM, Ma L, Li Y et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J. Immunol.182(3), 1314–1324 (2009).
   PubMed Web of Science ®Google Scholar
• Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest.115(10), 2914–2923 (2005).
   PubMed Web of Science ®Google Scholar
• Yada A, Ebihara S, Matsumura K et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgRIIB- and FcgRI/III-mediated immune complex uptake. Cell Immunol.225(1), 21–32 (2003).
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med.359(3), 242–251 (2008).
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science298(5601), 2199–2202 (2002).
   PubMed Web of Science ®Google Scholar
• Chevrier S, Genton C, Kallies A et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc. Natl Acad. Sci. USA106(10), 3895–3900 (2009).
   PubMed Web of Science ®Google Scholar
• Hu CY, Rodriguez-Pinto D, Du W et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest.117(12), 3857–3867 (2007).
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B-cell immunotherapy. J. Immunol.174(2), 817–826 (2005).
   PubMed Web of Science ®Google Scholar
• Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev.8(6), 515–519 (2009).
   PubMed Web of Science ®Google Scholar
• Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation82(12), 1769–1773 (2006).
   PubMed Web of Science ®Google Scholar
• Hippen BE, DeMattos A, Cook WJ, Kew CE 2nd, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am. J. Transplant.5(9), 2248–2252 (2005).
   PubMed Web of Science ®Google Scholar
• Martins HL, Silva C, Martini D, Noronha IL. Detection of B-lymphocytes (CD20+) in renal allograft biopsy specimens. Transplant Proc.39(2), 432–434 (2007).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant.8(12), 2607–2617 (2008).
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Kambham N, Li L et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int.74(5), 664–673 (2008).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr. Transplant.8(1), 9–21 (2004).
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol.122(1), 62–74 (2007).
   PubMed Web of Science ®Google Scholar
• Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation83(9), 1277–1280 (2007).
   PubMed Web of Science ®Google Scholar
• Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation87(10), 1555–1561 (2009).
   PubMed Web of Science ®Google Scholar
• Doxiadis, II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr. Opin. Immunol.17(5), 536–540 (2005).
   PubMed Web of Science ®Google Scholar
• Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin. Transplant.20(Suppl. 17), 7–12 (2006).
   PubMedGoogle Scholar
• Doxiadis II, Claas FH. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr. Opin. Organ Transplant14(4), 410–413 (2009).
   PubMed Web of Science ®Google Scholar
• Haririan A, Nogueira J, Kukuruga D et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am. J. Transplant.9(3), 536–542 (2009).
   PubMedGoogle Scholar
• DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost.87(1), 52–57 (2002).
   PubMed Web of Science ®Google Scholar
• Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood113(1), 11–17 (2009).
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N. Engl. J. Med.318(15), 947–950 (1988).
   PubMed Web of Science ®Google Scholar
• Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am. J. Transplant.3(8), 1017–1023 (2003).
   PubMed Web of Science ®Google Scholar
• Beimler JH, Morath C, Schmidt J et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and rituximab. Transplantation87(5), 668–671 (2009).
   PubMed Web of Science ®Google Scholar
• Tanriover B, Wright SE, Foster SV et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc.40(10), 3393–3396 (2008).
   PubMed Web of Science ®Google Scholar
• Ravichandran P, Natrajan T, Jaganathan R. Combination treatment of low dose anti-thymocyte globulin (ATG), rituximab and high dose sirolimus as induction agents in immune-conditioned recipients. Int. Immunopharmacol.6(13–14), 1973–1976 (2006).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib. Nephrol.162, 61–74 (2009).
   PubMed Web of Science ®Google Scholar
• Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation85(12), 1745–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Yoon HE, Hyoung BJ, Hwang HS et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J. Korean Med. Sci.24(Suppl.), S148–S155 (2009).
   Google Scholar
• Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc.40(7), 2218–2221 (2008).
   PubMed Web of Science ®Google Scholar
• Amante AJ, Ejercito R. Management of highly sensitized patients: Capitol Medical Center experience. Transplant Proc.40(7), 2274–2280 (2008).
   PubMed Web of Science ®Google Scholar
• Ignjatovic L, Kovacevic Z, Jovanovic D et al. Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kidney recipients. Vojnosanit Pregl.66(2), 117–122 (2009).
   PubMed Web of Science ®Google Scholar
• Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation86(6), 820–825 (2008).
   PubMed Web of Science ®Google Scholar
• Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation77(4), 542–548 (2004).
   PubMed Web of Science ®Google Scholar
• Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant.9(1), 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose–escalating, single- and repeated-dose study. Arthritis Rheum.58(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature404(6781), 995–999 (2000).
   PubMed Web of Science ®Google Scholar
• Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs9(11), 1216–1227 (2008).
   PubMed Web of Science ®Google Scholar
• Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol. Pathol.37(1), 89–99 (2009).
   PubMed Web of Science ®Google Scholar
• Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B-cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther.9(7), 909–919 (2009).
   PubMed Web of Science ®Google Scholar
• Dall’Era M, Chakravarty E, Wallace D et al. Reduced B-lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum.56(12), 4142–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Boskovic S, Smith NR, Kawai T et al. Inhibitory effects of atacicept (TACI-Ig) on circulating antibodies, B cells and plasma cells in allosensitized cynomolgous monkeys. Am. J. Transplant.8(Suppl. 2), 177–336 (2008).
   PubMedGoogle Scholar